Financials in USD. Standardized financial statements.
A compact view of how Chimeric Therapeutics Limited turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue? | $3.97M | $0 | $4.51M | $2.62M | $0 | $0 |
| Revenue Growth? | 0.0% | -100.0% | +72.2% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $846,763 | $3,922 | $0 | $949,762 | $846,960 | $0 |
| Gross Profit? | $3.12M | -$3,922 | $4.51M | $1.67M | -$846,960 | $0 |
| Gross Margin? | +78.7% | 0.0% | +100.0% | +63.7% | 0.0% | 0.0% |
| Operating Expenses? | $18.23M | $20.72M | $29.49M | $17.19M | $15.11M | $64,007 |
| Operating Income? | -$15.11M | -$20.72M | -$25.08M | -$15.09M | -$15.11M | -$64,010 |
| EBITDA? | -$9.08M | -$11.22M | -$24.02M | -$13.62M | -$14.26M | -$64,010 |
| Income Before Tax | -$10.32M | -$21.23M | -$25.41M | -$15.73M | -$15.11M | -$64,007 |
| Income Tax Expense | $110,809 | -$8.70M | $92,820 | $163,720 | $0 | $0 |
| Net Income? | -$10.43M | -$12.53M | -$25.50M | -$15.90M | -$15.11M | -$64,007 |
| EPS? | $-0.77 | $-1.80 | $-5.89 | $-4.42 | $-4.64 | $-0.02 |
| Diluted EPS? | $-0.77 | $-1.80 | $-5.89 | $-4.42 | $-4.64 | $-0.02 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality